Table 1. Correlation between AurkA overexpression and clinical/pathological features of breast cancer tissues (N = 89).

		AurkA+ BCs
BCs, N = 89		46,07% (41/89)
Clinical Histotypes	Triple Negative	31,58% of TN 29,27% (12/41)
	Luminal A–B	54,17% of Luminal 31,71% (13/41)
	Her2	59,26% of Her2+ 39,02% (16/41)
Grading	G1–G2	26,83% (11/41)
	G3	73,17% (30/41)
Ki67	>15%	63,42% (26/41)
	≤15%	36,59% (15/41)
Tumor Size (mm)1	<1	4,88% (2/41)
	1–2	36,59% (15/41)
	>2	56,10% (23/41)
	1ND	1/41
Linfonodal status (N)2	N0	39,02% (16/41)
	N1–3	56,10% (23/41)
	2ND	2/41